| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/RHEUMATOLOGY/35.11.1067 |
| P698 | PubMed publication ID | 8948291 |
| P2093 | author name string | G Steiner | |
| J S Smolen | |||
| A Studnicka-Benke | |||
| P Petera | |||
| P433 | issue | 11 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | 1067-1074 | |
| P577 | publication date | 1996-11-01 | |
| P1433 | published in | British Journal of Rheumatology | Q27709787 |
| P1476 | title | Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus | |
| P478 | volume | 35 |
| Q85410500 | 4G/5G plasminogen activator inhibitor-1 and -308 A/G tumor necrosis factor-α promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis |
| Q34089816 | A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs |
| Q33851587 | Abnormal production of pro- and anti-inflammatory cytokines by lupus monocytes in response to apoptotic cells |
| Q36587768 | Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling. |
| Q100634388 | Analysis of gene expression from systemic lupus erythematosus synovium reveals myeloid cell-driven pathogenesis of lupus arthritis |
| Q33960066 | Anti-TNF-alpha therapies in systemic lupus erythematosus |
| Q41837557 | Anti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation |
| Q58190397 | Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus |
| Q37773296 | Anticytokine therapies in systemic lupus erythematosus |
| Q59812771 | CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus |
| Q35617573 | Cytokine disturbances in systemic lupus erythematosus |
| Q57789918 | Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor |
| Q37741799 | Cytokines as therapeutic targets in SLE. |
| Q36659210 | Cytokines in systemic lupus erythematosus |
| Q33912101 | Cytomegalovirus infection in pediatric rheumatic diseases: a review |
| Q47850544 | Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus |
| Q36433143 | Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus |
| Q35677025 | Discoid lupus erythematosus-like eruption induced by infliximab |
| Q77696979 | Drug-induced systemic lupus erythematosus associated with etanercept therapy |
| Q35585133 | Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus |
| Q35940072 | Dyslipoproteinemia and premature atherosclerosis in pediatric systemic lupus erythematosus |
| Q37582576 | Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. |
| Q47810617 | Effects of oral Lactobacillus administration on antioxidant activities and CD4+CD25+forkhead box P3 (FoxP3)+ T cells in NZB/W F1 mice |
| Q89483209 | Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers |
| Q33393060 | Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-α and TNF-α in systemic lupus erythematosus |
| Q44586795 | Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus |
| Q33960009 | Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus |
| Q63407527 | Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy |
| Q33379277 | Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. |
| Q37239812 | Familial aggregation of high tumor necrosis factor alpha levels in systemic lupus erythematosus |
| Q38135706 | Future prospects in biologic therapy for systemic lupus erythematosus |
| Q36206615 | Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus |
| Q33682879 | Genetic regulation of serum cytokines in systemic lupus erythematosus |
| Q34108801 | Genetics and systemic lupus erythematosus |
| Q73881319 | Genetics and systemic lupus erythematosus |
| Q33893349 | Genetics of systemic lupus erythematosus. Clinical implications |
| Q35675014 | HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response. |
| Q47927593 | Higher genetic susceptibility to inflammation in mild disease activity of systemic lupus erythematosus |
| Q33788323 | IFN priming is necessary but not sufficient to turn on a migratory dendritic cell program in lupus monocytes |
| Q37772082 | IL-10 and TNFalpha genotypes in SLE. |
| Q37478985 | Immunoregulatory role of TNFalpha in inflammatory kidney diseases |
| Q82253147 | Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state |
| Q90011071 | Inflammatory bowel disease pathobiology: the role of the interferon signature |
| Q35071454 | Influenza A (H1N1) virus infection triggers severe pulmonary inflammation in lupus-prone mice following viral clearance |
| Q92404751 | Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1 |
| Q36095071 | Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosus |
| Q33555406 | Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity |
| Q35637001 | MHC class II, tumour necrosis factor alpha, and lymphotoxin alpha gene haplotype associations with serological subsets of systemic lupus erythematosus |
| Q64283956 | Mechanisms of hypertension in autoimmune rheumatic diseases |
| Q82287091 | Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility |
| Q38430919 | Meta-analysis of TNF-α promoter -308A/G polymorphism and SLE susceptibility in Asian populations |
| Q37363894 | Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations |
| Q28216909 | Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus |
| Q73537465 | Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis |
| Q34236658 | Monoclonal antibody therapy |
| Q81609248 | New therapies for systemic lupus erythematosus |
| Q35039863 | Newer drugs for the treatment of lupus nephritis |
| Q36952629 | Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. |
| Q82165564 | Partial construction of apoptotic pathway in PBMC obtained from active SLE patients and the significance of plasma TNF-alpha on this pathway |
| Q64085159 | RasGRP3 in peripheral blood mononuclear cells is associated with disease activity and implicated in the development of systemic lupus erythematosus |
| Q36392411 | Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus |
| Q46615185 | Retinal degeneration in experimental coronavirus retinopathy (ECOR) is associated with increased TNF-alpha, soluble TNFR2 and altered TNF-alpha signaling |
| Q74242486 | Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky |
| Q24804939 | SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus |
| Q82975773 | Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis |
| Q36151613 | Serum Cyr61 is associated with clinical disease activity and inflammation in patients with systemic lupus erythematosus |
| Q44155461 | Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF-308A in systemic lupus erythematosus. |
| Q38131100 | Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment |
| Q39053118 | Systemic lupus erythematosus biomarkers: the challenging quest |
| Q36673286 | Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. |
| Q42703356 | TNF-α - 308 G > A and IFN-γ + 874 A > T gene polymorphisms in Egyptian patients with lupus erythematosus |
| Q35795451 | TNF-α and TGF-β counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus |
| Q55379196 | TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. |
| Q28069849 | TNF-α gene polymorphisms and expression |
| Q92602774 | TNF-α promoter polymorphisms (G-238A and G-308A) are associated with susceptibility to Systemic Lupus Erythematosus (SLE) and P. falciparum malaria: a study in malaria endemic area |
| Q35867539 | The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus |
| Q37395321 | The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. |
| Q83466907 | The possible role of ChemR23/Chemerin axis in the recruitment of dendritic cells in lupus nephritis |
| Q35294438 | The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus |
| Q36641608 | The role of tumor necrosis factor-alpha in systemic lupus erythematosus |
| Q36611056 | Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus |
| Q34731092 | Therapy of systemic lupus erythematosus: a look into the future |
| Q53983532 | Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. |
| Q43845628 | Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis |
| Q33782338 | Tumour necrosis factor and other cytokines in murine lupus |
| Q37808291 | Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. |
| Q56959883 | [Biologics therapy for systemic lupus erythematosus. Current situation] |
| Q82663605 | [Systemic lupus erythematosus--activity and outcome] |
Search more.